Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
415
datasets available to search
ShareScore release 0.9.0
Dataset results
415 results for “CRC”
Health Literacy Interventions to Overcome Disparities in CRC Screening
ClinicalTrials.gov study NCT02360605. IPD Sharing: NO. Countries: 1. Publications: 26.
Prognostic Value of Neurometabolic Networks in CRC (PVNM-CRC)
ClinicalTrials.gov study NCT06930586. IPD Sharing: YES. Countries: 1. Publications: 4.
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
ClinicalTrials.gov study NCT02860546. IPD Sharing: YES. Countries: 1. Publications: 1.
Scaling CRC Screening Through Outreach, Referral, and Engagement (SCORE)
ClinicalTrials.gov study NCT04406714. IPD Sharing: YES. Countries: 1. Publications: 15.
Immunostaining images from CRC patients stained with AGR2 and SGTA antibodies
Open the record for dataset details and reuse information.
Histological image tiles for TCGA-CRC-DX, color-normalized, sorted by MSI status, train/test split
<p>These are histological images of colorectal cancer, derived from the TCGA database at https://portal.cdc.cancer.gov. Tumor tissue was outlined manually and the tumor region was cut into tiles of 256 µm edge length, saved as 512 px images (effective magnification 0.5 µm/px). All image tiles were color-normalized with the Macenko method. Patients were split into training and test set in a 2:1 ratio. For all patients, MSI status was acquired (patients with MSI-H = MSIH; patients with MSI-L and MSS = NonMSIH) and all tiles inherited the label of the parent patient. Then, tiles in the training set were randomly undersampled to equalize classes. The test set was not undersampled. Further info: www.kather.ai</p>
COLSCREEN: 16S-sequencing of fecal microbiota from a population-based CRC screening program
<p><span>The research cohort (COLSCREEN study) was recruited among individuals that participated during 2016-2020 in the ongoing population-based CRC screening program overseen by the Catalan Institute of Oncology in L’Hospitalet del Llobregat, Barcelona, Spain. This program invites men and women between the ages of 50 and 69 to partake in the immunochemical fecal occult blood test (FIT). In the event of a positive FIT result (≥ 20 μg Hb/g feces), the participants are then recommended to undergo colonoscopy. Participants of the COLSCREEN study (N=997) were invited to participate after receiving a positive FIT result. Since CRC diagnosis is rare in screening, this cohort includes patients diagnosed clinically from the CRC Functional Unit (N=45). Furthermore, a subset of participants with a negative FIT is also included (N=140). All of them underwent a colonoscopy and participants were categorized based on the risk stratification proposal by Castells et al. after careful review of the colonoscopy and histopathology reports. All participants who agreed to take part of the COLSCREEN study provided written informed consent and donated a fecal and blood sample at recruitment (samples obtained before colonoscopy) and answered an epidemiological questionnaire. Clinically diagnosed CRC patients usually underwent a colonoscopy before recruitment, and the fecal samples were obtained prior surgery. In the present study, we excluded those participants that reported having used antibiotics or probiotics one month before sampling. </span></p>
Cellular population data (Agent-based model CRC)
Open the record for dataset details and reuse information.
CRUK ACRCelerate CRC GEMM bulk RNAseq
<p>A comprehensive dataset comprising transcriptomic analysis of a world-leading collection of preclinical genetically engineered mouse models (GEMMs) of colorectal cancer (CRC). These patient-relevant models are driven by the mutation of key genes, or aberrant regulation of pathways central to human disease, including, but not limited to APC, TP53, KRAS, BRAF, TGFBR1 and NOTCH. Models within this cohort represent all stages of CRC, spanning from early lesion to late-stage metastatic disease; organoid, tumouroid, orthotopic engrafted disease and ultimately autochthonous primary and disseminated tumours. Moreover, models which discriminate key clinical features such as mismatch repair deficiency and proficiency (MMRd/MMRp), colitis association and anatomical location (right-sided/left-sided) are included.</p> <p>A schematic of available models appears as Figure 1, with further details found in Table 1.</p> <p>For access to the data set please contact: <a>gemmdata@crukscotlandinstitute.ac.uk</a></p> <p> </p> <p> </p> <p> </p> <p> </p>
SIRT2 is required for NaBT-induced CRC cell differentiation
<p>Activation of the Wnt/β-catenin pathway is one of the hallmarks of colorectal cancer (CRC). Sirtuin 2 (SIRT2) protein has been shown to inhibit CRC proliferation. Previously, we reported that SIRT2 plays an important role in the maintenance of normal intestinal cell homeostasis. Here, we show that SIRT2 is a direct target gene of Wnt/β-catenin signaling in CRC cells. Inhibition or knockdown of Wnt/β-catenin increased SIRT2 promoter activity and mRNA and protein expression, whereas activation of Wnt/β-catenin decreased SIRT2 promoter activity and expression. β-catenin was recruited to the promoter of SIRT2 and transcriptionally regulated SIRT2 expression. Wnt/β-catenin inhibition increased mitochondrial oxidative phosphorylation (OXPHOS) and CRC cell differentiation. Moreover, inhibition of OXPHOS attenuated the differentiation of CRC cells induced by Wnt/β-catenin inhibition. In contrast, inhibition or knockdown of SIRT2 decreased, while overexpression of SIRT2 increased, OXPHOS activity and differentiation in CRC cells. Consistently, inhibition or knockdown or SIRT2 attenuated the differentiation induced by Wnt/β-catenin inhibition. These results demonstrate that SIRT2 is a novel target gene of the Wnt/β-catenin signaling and contributes to the differentiation of CRC cells.</p>
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
ClinicalTrials.gov study NCT07277322. IPD Sharing: NO. Countries: 1. Publications: 8.
"High Levels of EMT-TFs for the Diagnosis of Colorectal Cancer (CRC)"
ClinicalTrials.gov study NCT04323813. IPD Sharing: NO. Countries: 1. Publications: 1.
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
ClinicalTrials.gov study NCT01750918. IPD Sharing: YES. Countries: 8. Publications: 0.
mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC
ClinicalTrials.gov study NCT04895137. IPD Sharing: NO. Countries: 1. Publications: 12.
A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients
ClinicalTrials.gov study NCT03047837. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study on a Blood-based Dual-target Test for CRC Detection
ClinicalTrials.gov study NCT05508503. IPD Sharing: UNDECIDED. Countries: 1. Publications: 6.
Epigenetic Signature for CRC Early Detection
ClinicalTrials.gov study NCT07224854. IPD Sharing: NO. Countries: 1. Publications: 2.
Evaluation of Somatic Mutation Spectrum as Biomarker for Survival Outcome in Chinese CRC
ClinicalTrials.gov study NCT04228614. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy
ClinicalTrials.gov study NCT00188331. IPD Sharing: Not stated. Countries: 2. Publications: 4.
Community Dissemination of an Evidence-based Colorectal Cancer (CRC) Screening Intervention
ClinicalTrials.gov study NCT01351220. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.